 This observation may
lead one to believe that the CREST results reflect the best
possible selection of candidates for CAS. This is particularly
true when these results are compared with the considerably
worse results presented in SAPPHIRE, the only other
extant trial with a large number of asymptomatic patients.
Data published by the Society for Vascular Surgery
Outcomes Committee demonstrated that real-world CAS
was associated with a significantly higher rate of major
complications than CEA in asymptomatic